DCOY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026
Revenue
307.4K
+35.1%
227.6K
0
Cost of Revenue
0
0
0
Gross Profit
307.4K
+35.1%
227.6K
0
Operating Expenses
3.3M
+26.2%
2.6M
+15.2%
2.3M
R&D
1.6M
+20.7%
1.3M
+74.0%
749.8K
SG&A
1.7M
+31.6%
1.3M
-13.5%
1.5M
Operating Income
-3013136
-25.4%
-2403392
-5.2%
-2283739
EBITDA
-2988273
-25.0%
-2389760
-4.9%
-2277815
Net Income
-2987830
-25.9%
-2373800
-6.7%
-2224628
EPS (Basic)
$-3.53
+20.9%
$-4.46
-6.7%
$-4.18
EPS (Diluted)
$-3.53
+20.9%
$-4.46
-6.7%
$-4.18
Shares (Diluted)
845.4K
+58.9%
532.0K
+0.0%
532.0K
Decoy Therapeutics (DCOY) — Financials